CorMedix Inc.
CRMD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -1.13 | 0.11 | -0.02 |
| FCF Yield | 3.44% | 3.58% | 4.91% | -1.13% |
| EV / EBITDA | 17.16 | 33.04 | 16.15 | 33.66 |
| Quality | ||||
| ROIC | 17.14% | 8.61% | 17.44% | 15.19% |
| Gross Margin | 89.26% | 95.31% | 95.91% | 96.23% |
| Cash Conversion Ratio | 0.28 | 1.51 | 0.96 | -0.42 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,832.33% | 1,392.80% | 1,026.35% | 772.69% |
| Free Cash Flow Growth | 1.28% | 51.92% | 450.73% | 58.82% |
| Safety | ||||
| Net Debt / EBITDA | 1.75 | -7.74 | -3.16 | -2.95 |
| Interest Coverage | 54.15 | 2,929.62 | 2,011.12 | 1,292.70 |
| Efficiency | ||||
| Inventory Turnover | 0.39 | 0.19 | 0.21 | 0.15 |
| Cash Conversion Cycle | 206.19 | 281.74 | 438.85 | 599.07 |